Obesity Clinical Trial
Official title:
The Effect of Bariatric Procedures on Gut Microbiota, Gut Peptide and Metabolism in Obese Individuals in United Arab Emirates and Lebanon
NCT number | NCT04200521 |
Other study ID # | 1234 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | October 27, 2019 |
Est. completion date | October 2020 |
Overweight and obesity are worldwide health problems that can affect negatively quality of
life. With increasing prevalence of obesity and the failure of compliance to lifestyle,
bariatric surgeries have become the treatment of choice to help achieve long term sustainable
weight loss. In some cases of bariatric surgery, weight loss stops and there are cases in
which obesity manifests itself again; the mechanism underlying the re-appearance of obesity
is not known. Recently, the gut microbiota, has been implicated in the etiology of obesity
and metabolic syndrome due to its important role in digestion, metabolism and regulating gut
peptides and hormones. In accordance with this, it has been shown in mice that obesity can be
associated with dysbiosis (Imbalance in gut bacteria) and there has been successful reduction
of weight in interventions when microbiota was manipulated.
Hypothesis:
1. Emirati participants will have unique microbiota and gut peptides when compared to
Lebanese participants.
2. The microbiota and gut peptides variability is significantly different between those
with normal weight compared to obese participants undergoing bariatric surgery.
3. The bariatric procedure will have a significant effect on the variability of microbiota,
gut peptides, blood chemistry, dietary intake and metabolism among the obese
participants.
Objectives of the study:
1. Determine the gut microbiota composition of Emirati healthy normal weight participants
and compare to that of Lebanese via Illumina sequencing NGS (Next Generation Sequencing
of the 16S rRNA gene) of the microbiota from the stool samples.
2. Determine the gut microbiota composition of Emirati obese participants and compare to
that of Lebanese counterparts using NGS.
3. Determine the effect of bariatric procedure in UAE and Lebanon respectively on gut
microbiota (using NGS), gut peptides in plasma, blood chemistry and metabolism using
indirect calorimetry and food intake.
Importance of this research:
The microbiota and gut peptides variability is determined by body weight and ethnicity of the
studied populations. It is hypothesized that bariatric surgery will have a significant effect
on the variability of microbiota, gut peptides, blood chemistry, dietary intake and
metabolism. This study will be a pioneering research in UAE and Lebanon to assist in finding
population tailored therapeutic strategies that target the gut microbiota and treat obesity.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | October 2020 |
Est. primary completion date | May 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Emirati residing in UAE and Lebanese residing in Lebanon - 18 to 60 years old - from both genders - Free of antibiotics for at least 3 months - Two BMI categories: 1) obese with a BMI of =35 kg/m2 planning to undergo a bariatric procedure 2) healthy counterparts with a BMI of 18.5-24.9 kg/m2 Exclusion Criteria: - Individuals who do not meet the inclusion criteria - Consumption of alcohol above the recommended amount per day (>½ ounce of ethanol for females and >1 ounce for men) - Pregnant at the time of the study - Significant voluntary weight loss (=5% in the preceding 3 months) - Not willing to provide written consent to the study |
Country | Name | City | State |
---|---|---|---|
Lebanon | Middle East Institute of Health, University Hospital | Beirut | |
United Arab Emirates | Al Qassimi Hospital | Sharja, |
Lead Sponsor | Collaborator |
---|---|
Zayed University |
Lebanon, United Arab Emirates,
Adlerberth I, Wold AE. Establishment of the gut microbiota in Western infants. Acta Paediatr. 2009 Feb;98(2):229-38. doi: 10.1111/j.1651-2227.2008.01060.x. Review. — View Citation
Aydin S. Can Peptides and Gut Microbiota Be Involved in the Etiopathology of Obesity? Obes Surg. 2017 Jan;27(1):202-204. doi: 10.1007/s11695-016-2429-0. — View Citation
Bauer PV, Hamr SC, Duca FA. Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota. Cell Mol Life Sci. 2016 Feb;73(4):737-55. doi: 10.1007/s00018-015-2083-z. Epub 2015 Nov 5. Review. — View Citation
Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012 Jul-Aug;3(4):279-88. Epub 2012 May 14. Review. — View Citation
Cannon CP, Kumar A. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Clin Cornerstone. 2009;9(4):55-68; discussion 69-71. — View Citation
Corfe BM, Harden CJ, Bull M, Garaiova I. The multifactorial interplay of diet, the microbiome and appetite control: current knowledge and future challenges. Proc Nutr Soc. 2015 Aug;74(3):235-44. doi: 10.1017/S0029665114001670. Epub 2015 Jan 23. Review. — View Citation
Damms-Machado A, Mitra S, Schollenberger AE, Kramer KM, Meile T, Königsrainer A, Huson DH, Bischoff SC. Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption. Biomed Res Int. 2015;2015:806248. doi: 10.1155/2015/806248. Epub 2015 Feb 1. — View Citation
Lovibond, S.H. & Lovibond, P.F. Manual for the Depression Anxiety & Stress Scales. (2nd Ed.)Sydney. Psychology Foundation 1995.
Patrone V, Vajana E, Minuti A, Callegari ML, Federico A, Loguercio C, Dallio M, Tolone S, Docimo L, Morelli L. Postoperative Changes in Fecal Bacterial Communities and Fermentation Products in Obese Patients Undergoing Bilio-Intestinal Bypass. Front Micro — View Citation
Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009 May;9(5):313-23. doi: 10.1038/nri2515. Review. Erratum in: Nat Rev Immunol. 2009 Aug;9(8):600. — View Citation
Seganfredo FB, Blume CA, Moehlecke M, Giongo A, Casagrande DS, Spolidoro JVN, Padoin AV, Schaan BD, Mottin CC. Weight-loss interventions and gut microbiota changes in overweight and obese patients: a systematic review. Obes Rev. 2017 Aug;18(8):832-851. do — View Citation
Wilson MM, Thomas DR, Rubenstein LZ, Chibnall JT, Anderson S, Baxi A, Diebold MR, Morley JE. Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr. 2005 Nov;82(5):10 — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in Gut Microbiota composition in obese participants | Using Illumina sequencing NGS (Next Generation Sequencing of the 16S rRNA gene) of the microbiota from the stool samples. | Baseline and 3 months post bariatric surgery | |
Secondary | Changes in plasma level of CCK Hormone in obese participants | Via Blood test | Baseline and 3 months post bariatric surgery | |
Secondary | Changes in plasma level of PYY Hormone in obese participants | Via Blood test | Baseline and 3 month post bariatric surgery | |
Secondary | Changes in plasma level of Ghrelin Hormone in obese participants | Via Blood test | Baseline and 3 month post bariatric surgery | |
Secondary | Changes in plasma level of Leptin Hormone in obese participants | Via Blood test | Baseline and 3 month post bariatric surgery | |
Secondary | Changes in plasma level of Insulin Hormone in obese participants | Via Blood test | Baseline and 3 month post bariatric surgery | |
Secondary | Changes in plasma level of GLP1 Hormone in obese participants | Via Blood test | Baseline and 3 month post bariatric surgery | |
Secondary | Changes in plasma level of GLP2 Hormone in obese participants | Via Blood test | Baseline and 3 month post bariatric surgery | |
Secondary | Changes in plasma level of fasting Cholesterol in obese participants | Via Blood test | Baseline and 3 month post bariatric surgery | |
Secondary | Changes in plasma level of Fasting Blood Sugar in obese participants | Using Blood test | Baseline and 3 month post bariatric surgery | |
Secondary | Assessing changes in Energy Expenditure in obese participants | By using Indirect Calorimeter | Baseline and 3 months post bariatric surgery | |
Secondary | Assessing changes in appetite in obese participants | Using Simplified Nutritional Appetite Questionnaire. Following numerical scale: a =1, b =2, c = 3, d =4, e = 5. The sum of the scores for the individual items constitutes the SNAQ score. SNAQ score 14 indicates significant risk of at least 5% weight loss within six months. | Baseline and 3 months post bariatric surgery | |
Secondary | Changes in Dietary Intake in obese participants | Using 24 Hour dietary recall method. The method consists of precisely recalling, describing and quantifying the intake of foods and beverages consumed in the 24 hour period. | Baseline and 3 months post bariatric surgery | |
Secondary | Measure the changes in emotional states of Depression, Anxiety and Stress.in obese participants | Using Depression, Anxiety and Stress Scale - 21 Items (DASS-21) Each of the three DASS scales contains 14 items, divided into subscales of 2-5 items with similar content. Subjects are asked to use 4-point severity/frequency scales to rate the extent to which they have experienced each state over the past week. Scores for Depression, Anxiety and Stress are calculated by summing the scores for the relevant items. | Baseline and 3 months post bariatric surgery | |
Secondary | Changes in Body Composition in obese participants | Via Bio-electrical Impedance Analysis | Baseline and 3 months post bariatric surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |